Dyslipidemia
📧 Sign up to get email alerts when something new happens for Dyslipidemia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-09-23FDA Approved: FENOFIBRATE — Supplemental Application (AvKARE)
The FDA has approved a supplemental application for AvKARE's fenofibrate product, signaling an update to the approved formulation/manufactur…
-
FDA approval · 2019-09-19FDA Approved: FENOFIBRATE — Supplemental Application (Cipla USA Inc.)
FDA approved a supplemental application for fenofibrate from Cipla USA Inc. The approval indicates an update or addition via a supplemental …
-
FDA approval · 2019-09-06FDA Approved: FENOFIBRATE — Original Application (Dr. Reddy's Laboratories Inc.)
FDA approved the original application for fenofibrate by Dr. Reddy's Laboratories Inc., authorizing the product as a generic.
-
FDA approval · 2019-08-15FDA Approved: FENOFIBRATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approves a supplemental application for fenofibrate by Mylan Pharmaceuticals, confirming continued access to this generic triglyceride-l…
-
CLINICAL_TRIALS trial_result · 2019-07-19Clinical Trial Update: Change of Fructose to Fat in South Asians [NA]
A completed clinical trial from The Rogosin Institute investigated a dietary change from fructose to fat in South Asians with elevated trigl…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-06-26Clinical Trial Update: Fenofibrate Treatment in SCI [Phase 2, Phase 3]
Phase 2/3 trial investigating fenofibrate for spinal cord injury with dyslipidemia completed, with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-06-19Clinical Trial Update: Bococizumab HIV Evaluation (B-HIVE) Study [Phase 3]
Phase 3 clinical trial update for bococizumab (B-HIVE) evaluating HIV-related dyslipidemia and cardiovascular disease; study terminated with…
-
CLINICAL_TRIALS trial_result · 2019-06-10Clinical Trial Update: Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia [Phase 3]
Phase 3 trial update of a fixed-dose combination (fimasartan/amlodipine/rosuvastatin) in patients with essential hypertension and dyslipidem…
-
CLINICAL_TRIALS trial_result · 2019-06-03Clinical Trial Update: Impact of Consumption of Beta-glucans on the Intestinal Microbiota and Glucose and Lipid Metabolism [NA]
A completed clinical trial assessed the impact of beta-glucan consumption on the intestinal microbiota and glucose and lipid metabolism in i…
-
CLINICAL_TRIALS trial_result · 2019-05-21Clinical Trial Update: The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control [Phase 4]
A Phase 4 clinical trial evaluated magnesium's effect on blood pressure, cholesterol, and glucose control in patients with cardiovascular ri…
-
FDA approval · 2019-05-15FDA Approved: LIPOFEN — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Lipofen (fenofibrate) filed by ANI Pharmaceuticals, Inc., marking a regulatory action on thi…
-
FDA approval · 2019-05-15FDA Approved: FENOFIBRATE — Supplemental Application (Cipla USA Inc.,)
FDA approved a supplemental application for fenofibrate from Cipla USA Inc., authorizing an updated generic fenofibrate product.
-
FDA approval · 2019-05-15FDA Approved: FENOFIBRATE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved a supplemental ANDA for fenofibrate from Glenmark Pharmaceuticals Inc., USA, authorizing a generic fenofibrate product.
-
FDA approval · 2019-05-15FDA Approved: FENOFIBRATE — Supplemental Application (Bostal LLC)
FDA approved a supplemental application for fenofibrate from Bostal LLC, indicating approved changes to the product's labeling/status.
-
CLINICAL_TRIALS trial_result · 2019-05-09Clinical Trial Update: Pilot Study of an Intervention Involving Cognitive Training and tDCS in Morbidly Obese Subjects [Phase 2]
Phase 2 pilot study evaluating the effects of cognitive training combined with transcranial direct current stimulation (tDCS) in morbidly ob…
-
CLINICAL_TRIALS trial_result · 2019-04-23Clinical Trial Update: Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a)) [Phase 3]
Phase 3 trial evaluating PCSK9 inhibition on arterial wall inflammation in patients with elevated Lp(a); study completed with results posted…
-
FDA approval · 2019-03-06FDA Approved: SIMVASTATIN — Supplemental Application (Biocon Pharma Inc,)
FDA approved Biocon Pharma Inc.'s supplemental application for simvastatin (ANDA 078034). The approval concerns Biocon's generic simvastatin…
-
FDA approval · 2019-03-01FDA Approved: FENOFIBRATE — Supplemental Application (Amneal Pharmaceuticals NY LLC)
The FDA approved a supplemental ANDA for fenofibrate from Amneal Pharmaceuticals NY LLC, authorizing changes to the approved generic product…
-
CLINICAL_TRIALS trial_result · 2019-02-21Clinical Trial Update: The Effect of Prednisone on Atherogenesis as Studied in the Macrophage Foam Cell Formation Model System. [EARLY_Phase 1]
An early-phase study examining the effect of prednisone on macrophage foam cell formation in a model of atherogenesis.
-
CLINICAL_TRIALS trial_result · 2019-02-21Clinical Trial Update: The Effects of Glycine on Atherosclerosis and Metabolic Syndrome-related Parameters. [Phase 2, Phase 3]
Phase 2/Phase 3 trial evaluating the effects of glycine on atherosclerosis and metabolic syndrome–related parameters. The current status of …
-
CLINICAL_TRIALS trial_result · 2019-02-20Clinical Trial Update: Randomized Comparison of Laparoscopic Sleeve Gastrectomy and Gastric Bypass for Morbid Obesity [NA]
ClinicalTrials.gov reports completed results of a randomized trial comparing laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass fo…
-
FDA approval · 2019-02-19FDA Approved: GEMFIBROZIL — Supplemental Application (NorthStar Rx LLC)
The FDA approved a supplemental application for gemfibrozil by NorthStar Rx LLC.
-
FDA approval · 2019-02-04FDA Approved: FENOFIBRATE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for Fenofibrate (NDA021695), a generic fenofibrate product.
-
CLINICAL_TRIALS trial_result · 2019-01-31Clinical Trial Update: Pharmacokinetics of Rosuvastatin and Atorvastatin in Pediatric Dyslipidemia Patients [Phase 1]
Phase 1 pharmacokinetic study of rosuvastatin and atorvastatin in pediatric patients with dyslipidemia has completed.
-
CLINICAL_TRIALS trial_result · 2019-01-31Clinical Trial Update: Rosuvastatin Adherence App Study in China [NA]
AstraZeneca-sponsored clinical trial in China evaluating a rosuvastatin adherence app for dyslipidemia/hyperlipidemia has completed, with re…